Clinical Trials Browser

Phase 1 × INDUSTRY × Lymphoma, Non-Hodgkin × Clear all

Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioblastoma, Glioma, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neuroectodermal Tumors, Primitive, Neoplasms, Neuroepithelial, Gliosarcoma, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT05397496 2026-03-17

Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies

Phase 1 Active not recruiting

61 enrolled

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05424822 2026-03-13

A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Phase 1 Active not recruiting

167 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

Clinical Trials

CLOVER-2

Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies

A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer

A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL)

A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies

A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies

Phase 1, Open-label, Dose-escalation Trial With CD38-SADA:177 Lu-DOTA Drug Complex in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma

A Mass Balance Study of DZD8586 in Healthy Male Participants (TAI-SHAN15)

PIC1 Injection Therapy for Relapsed/Refractory B-NHL

BAF_FRontier-1

Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)

A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers

An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma

Study of SGR-1505 in Mature B-Cell Neoplasms

Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies

A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors

TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

Study of AXT-1003 in Subjects With Advanced Malignant Tumors.

A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers

Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma

First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

A Study of LP-118 in Patients With Advanced Tumors

ON-5001

A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS

ELiPSE-1

SynKIR-310 for Relapsed/Refractory B-NHL

VIJAY-1

Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

KSV01 Injection for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)

Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies

ELM-1

Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL

VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)

IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies